Download FREE Sample
Table of Contents
1. Introduction
1.1. Introduction
1.2. Market Scope
1.2.1
Market Definition
1.2.2
Segments Covered
1.2.3
Regional Segmentation
1.3. Research Timeframe
1.4. Currency Considered
1.5. Study Limitations
1.6. Stakeholders
1.7. List of Abbreviations
1.8. Key Conferences and Events (2026-2027)
2.
Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.3. Market Estimation
2.3.1
Bottom-Up Approach
2.3.2
Top-Down Approach
2.4. Market Forecasting
3.
Executive Summary
3.1. Liver Disease Therapeutics
Market Snapshot (2026-2031)
3.2. Segment Overview
3.3. Regional Snapshot
3.4. Competitive Insights
4.
Market Overview
4.1. Market Dynamics
4.1.1.
Drivers
4.1.1.1.
Increasing
global incidence of liver disease
4.1.1.2.
Rising obesity rates and metabolic disorders
accelerating MASLD prevalence
4.1.1.3.
Growing
geriatric population with age-related hepatic comorbidities
4.1.1.4.
Government-led
vaccination and hepatitis screening initiatives
4.1.1.5.
Increasing adoption of precision medicine approaches
in liver disease treatment
4.1.2.
Restraints
4.1.2.1.
Lack
of clinically validated biomarkers
4.1.2.2. Adverse drug effects and
long-term adherence challenges
4.1.2.3. Limited reimbursement
coverage in emerging economies
4.1.3. Opportunities
4.1.3.1.
Rising global burden of liver cancer
4.1.3.2.
Growing integration of companion diagnostics in liver
disease therapeutics
4.1.3.3.
Expansion of healthcare infrastructure in emerging
economies
4.1.3.4.
Growth of telehepatology and decentralized care models
4.2. Key Market Trends
4.2.1.
Growing
adoption of targeted therapy and immuno-oncology combinations for
hepatocellular carcinoma
4.2.2. Shift from symptomatic
management to disease-modifying therapies
4.3. Unmet Market Needs
4.4. Industry Speaks
5. Global Liver Disease Therapeutics Market Size & Forecast (2024-2031),
By Disease Type, USD Billion
5.1. Introduction
5.2. Viral Hepatitis
5.3. Liver Cancer
5.4. Liver Cirrhosis
5.5. Steatohepatitis (MASLD/MASH)
6. Global Liver Disease Therapeutics Market Size & Forecast (2024-2031),
By Product, USD Billion
6.1. Introduction
6.2. Antiviral Drugs
6.3. Vaccines
6.4. Chemotherapy
6.5. Targeted Therapy
6.6. Immunosuppressants
6.7. Immunoglobulins
6.8. Corticosteroids
6.9. Other Products
7. Global Liver Disease Therapeutics Market Size & Forecast (2024-2031),
By Route of Administration, USD Billion
7.1. Introduction
7.2. Oral Formulations
7.3. Intravenous Infusion
8. Global Liver Disease Therapeutics Market Size & Forecast (2024-2031),
By Distribution Channel, USD Billion
8.1.
Introduction
8.2.
Hospital
Pharmacies
8.3.
Retail
Pharmacies
8.4. Online Pharmacies
9.
Global
Liver Disease Therapeutics Market Size & Forecast (2024-2031),
By Region, USD Billion
9.1. Introduction
9.2. North America Liver Disease Therapeutics Market Size & Forecast (2024-2031), By Country,
USD Billion
9.2.1.
US
9.2.1.1.
Market Size & Forecast, By Disease
Type (USD Billion)
9.2.1.2.
Market Size
& Forecast, By Product (USD Billion)
9.2.1.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.2.1.4.
Market Size & Forecast, By
Distribution Channel (USD Billion)
9.2.2.
Canada
9.2.2.1. Market Size
& Forecast, By Disease Type (USD Billion)
9.2.2.2.
Market Size
& Forecast, By Product (USD Billion)
9.2.2.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.2.2.4.
Market Size & Forecast, By
Distribution Channel (USD Billion)
9.3. Europe Liver Disease Therapeutics Market Size & Forecast (2024-2031), By Country,
USD Billion
9.3.1.
UK
9.3.1.1. Market Size
& Forecast, By Disease Type (USD Billion)
9.3.1.2.
Market Size
& Forecast, By Product (USD Billion)
9.3.1.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.3.1.4.
Market Size & Forecast, By
Distribution Channel (USD Billion)
9.3.2.
Germany
9.3.2.1. Market Size
& Forecast, By Disease Type (USD Billion)
9.3.2.2.
Market Size
& Forecast, By Product (USD Billion)
9.3.2.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.3.2.4.
Market Size & Forecast, By
Distribution Channel (USD Billion)
9.3.3.
France
9.3.3.1. Market Size
& Forecast, By Disease Type (USD Billion)
9.3.3.2.
Market Size
& Forecast, By Product (USD Billion)
9.3.3.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.3.3.4.
Market Size & Forecast, By
Distribution Channel (USD Billion)
9.3.4.
Italy
9.3.4.1. Market Size
& Forecast, By Disease Type (USD Billion)
9.3.4.2.
Market Size
& Forecast, By Product (USD Billion)
9.3.4.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.3.4.4.
Market Size & Forecast, By
Distribution Channel (USD Billion)
9.3.5.
Spain
9.3.5.1. Market Size
& Forecast, By Disease Type (USD Billion)
9.3.5.2.
Market Size
& Forecast, By Product (USD Billion)
9.3.5.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.3.5.4.
Market Size & Forecast, By
Distribution Channel (USD Billion)
9.3.6.
Rest of Europe
9.3.6.1. Market Size
& Forecast, By Disease Type (USD Billion)
9.3.6.2.
Market Size
& Forecast, By Product (USD Billion)
9.3.6.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.3.6.4.
Market Size & Forecast, By
Distribution Channel (USD Billion)
9.4. Asia Pacific (APAC) Liver Disease Therapeutics Market Size & Forecast (2024-2031), By Country,
USD Billion
9.4.1.
China
9.4.1.1. Market Size
& Forecast, By Disease Type (USD Billion)
9.4.1.2.
Market Size
& Forecast, By Product (USD Billion)
9.4.1.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.4.1.4.
Market Size & Forecast, By
Distribution Channel (USD Billion)
9.4.2.
Japan
9.4.2.1. Market Size
& Forecast, By Disease Type (USD Billion)
9.4.2.2.
Market Size
& Forecast, By Product (USD Billion)
9.4.2.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.4.2.4.
Market Size & Forecast, By
Distribution Channel (USD Billion)
9.4.3.
India
9.4.3.1. Market Size
& Forecast, By Disease Type (USD Billion)
9.4.3.2.
Market Size
& Forecast, By Product (USD Billion)
9.4.3.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.4.3.4.
Market Size & Forecast, By
Distribution Channel (USD Billion)
9.4.4.
Rest of Asia Pacific
9.4.4.1. Market Size
& Forecast, By Disease Type (USD Billion)
9.4.4.2.
Market Size
& Forecast, By Product (USD Billion)
9.4.4.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.4.4.4.
Market Size & Forecast, By
Distribution Channel (USD Billion)
9.5. Latin America (LATAM) Liver Disease Therapeutics Market Size & Forecast (2024-2031), USD Billion
9.5.1. Market Size
& Forecast, By Disease Type (USD Billion)
9.5.2.
Market Size
& Forecast, By Product (USD Billion)
9.5.3.
Market Size
& Forecast, By Route of Administration (USD Billion)
9.5.4.
Market Size & Forecast, By Distribution Channel (USD Billion)
9.6. Middle East & Africa (MEA) Liver Disease
Therapeutics Market Size & Forecast (2024-2031), USD Billion
9.6.1. Market Size
& Forecast, By Platform (USD Billion)
9.6.2.
Market Size
& Forecast, By Product (USD Billion)
9.6.3. Market Size
& Forecast, By Route of Administration (USD Billion)
9.6.4. Market Size & Forecast, By Distribution Channel (USD Billion)
10.
Competitive Landscape
10.1.
Key Players and their
Competitive Positioning
10.1.1.
Key Player Comparison
10.1.2.
Segment-wise Player Mapping
10.1.3.
Market Share Analysis (2025)
10.1.4.
Company Categorization Matrix
10.1.4.1.
Dominants/Leaders
10.1.4.2.
New Entrants
10.1.4.3.
Emerging Players
10.1.4.4.
Innovative Players
10.2.
Key Strategies Assessment, By
Player (2023-2026)
10.2.1.
New Product Launch
10.2.2.
Partnerships, Agreements,
& Collaborations
10.2.3.
Mergers & Acquisitions
10.2.4.
Geographic
Expansion
11.
Company
Profiles*
(Business Overview, Financial
Performance**, Products Offered, Recent Developments)
11.1.
Gilead Sciences, Inc.
11.2.
AbbVie Inc.
11.3.
Bristol-Myers Squibb Company
11.4.
F Hoffmann-La Roche Ltd
11.5.
Takeda Pharmaceutical Company
Limited.
11.6.
Johnson & Johnson
Services, Inc.
11.7.
Merck
& Co. Inc.
11.8.
Novartis AG
11.9.
Pfizer Inc.
11.10.
Sanofi
11.11.
Other Prominent Players
